Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.

Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, van Delden O, Ümütlü MR, Ben Khaled N, de Toni EN, Seidensticker R, Aghdassi A, Tran A, Bronowicki JP, Peynircioglu B, Sangro B, Pech M, Ricke J

Open source

DOI: 10.1016/j.jhepr.2023.100699
Published: 2023 May
Container: JHEP reports : innovation in hepatology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jhepr.2023.100699,
  title = {Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.},
  author = {Seidensticker M and Öcal O and Schütte K and Malfertheiner P and Berg T and Loewe C and Klümpen HJ and van Delden O and Ümütlü MR and Ben Khaled N and de Toni EN and Seidensticker R and Aghdassi A and Tran A and Bronowicki JP and Peynircioglu B and Sangro B and Pech M and Ricke J},
  year = {2023},
  journal = {JHEP reports : innovation in hepatology},
  doi = {10.1016/j.jhepr.2023.100699},
  url = {https://doi.org/10.1016/j.jhepr.2023.100699}
}

RIS

TY  - JOUR
TI  - Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
AU  - Seidensticker M
AU  - Öcal O
AU  - Schütte K
AU  - Malfertheiner P
AU  - Berg T
AU  - Loewe C
AU  - Klümpen HJ
AU  - van Delden O
AU  - Ümütlü MR
AU  - Ben Khaled N
AU  - de Toni EN
AU  - Seidensticker R
AU  - Aghdassi A
AU  - Tran A
AU  - Bronowicki JP
AU  - Peynircioglu B
AU  - Sangro B
AU  - Pech M
AU  - Ricke J
PY  - 2023
JO  - JHEP reports : innovation in hepatology
DO  - 10.1016/j.jhepr.2023.100699
UR  - https://doi.org/10.1016/j.jhepr.2023.100699
ER  -

APA

M, S., O, Ö., K, S., P, M., T, B., C, L., HJ, K., O, V. D., MR, Ü., N, B. K., EN, D. T., R, S., A, A., A, T., JP, B., B, P., B, S., M, P., & J, R. (2023). Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.. JHEP reports : innovation in hepatology. https://doi.org/10.1016/j.jhepr.2023.100699

Source records

pubmed · retrieved 2026-09-27T06:59:52.845Z